SCHEMBL6683561

SCHEMBL6683561

CCC1OC(=O)N(Cc2ccc(NC(=O)c3ccncc3)cc2)N=C1c1ccc(OC)c(OC(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ABL1 P00519 4/20 0.44
PDE4D Q08499 6/20 0.41
PDE4A P27815 5/20 0.41
PDE4B Q07343 5/20 0.41
PDE4C Q08493 5/20 0.41
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
ALOX15 P16050 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KCNH2 Q12809 1/20 0.40
NAMPT P43490 1/20 0.40
PDE3B Q13370 1/20 0.39
PDE11A Q9HCR9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6685841 0.97 LMNA (0.44) LMNAMAPK1HTTSMN1; SMN2L3MBTL1
SCHEMBL6689118 0.93 LMNA (0.51) LMNAMAPK1HTTSMN1; SMN2L3MBTL1
SCHEMBL144888 0.92 ABL1 (0.46) LMNAMAPK1HTTSMN1; SMN2ABL1
SCHEMBL6842687 0.90 LMNA (0.45) LMNAMAPK1HTTSMN1; SMN2L3MBTL1
SCHEMBL6687693 0.90 LMNA (0.46) LMNAMAPK1HTTSMN1; SMN2L3MBTL1
SCHEMBL6656570 0.90 NPC1 (0.45) LMNASMN1; SMN2L3MBTL1ABL1PDE4D
SCHEMBL6688125 0.90 PDE4D (0.39) MAPK1ABL1PDE4DPDE4APDE4B
SCHEMBL6656216 0.90 PDE4D (0.39) ABL1PDE4DPDE4APDE4BPDE4C
SCHEMBL6683848 0.90 LMNA (0.44) LMNAMAPK1HTTSMN1; SMN2L3MBTL1
SCHEMBL6841770 0.90 LMNA (0.46) LMNAMAPK1HTTSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B LMNA 2603/4885MAPK1 1267/4885HTT 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.